

P. Christopher H. Gottschalk, MD FAHS

Yale Neurology Group Phone (203) 785-4085 FAX -4937
Yale Physicians Bldg Cell (203) 605-9807
Lower Level
800 Howard Avenue
New Haven, CT 06519

Current Appointments & Academic Positions:

Yale New Haven Hospital (Attending Neurologist)	2009-present
Assistant Professor of Neurology, Yale School of Medicine	2015-present
Director, Yale Headache + Facial Pain Program	2011-present
Director, Yale Headache Medicine Fellowship Training Program	2012-present

Certifications

Fellow, American Headache Society (FAHS)	2015
<u>UCNS – Headache Medicine</u> (Subspecialty board)	2012
<u>American Board of Psychiatry and Neurology</u> (recertified March, 2007; valid thru 12/31/17)	2007
<u>American Society of Neuroimaging</u>	2006

Licensure

Primary MD – 035234, Connecticut
NPI 1831131176 ME – 0350190054

Education:

BS John Hopkins University (Organic Chemistry)	1984
Faculté La Sorbonne (Paris): Level A Diploma (19 th Century Literature & Poetry)	1985
MD Columbia University College of Physicians & Surgeons	1990

Career/Academic Appointments:

Internship: Internal Medicine, St. Vincent's Medical Center, New York City	1990-1991
Residency: Neurology, The Neurological Institute of New York (Columbia)	1991-1994
Research Fellowship: Functional Imaging of Substance Abuse Disorders (Columbia)	1994-1996
Assistant Professor, Psychiatry (Primary) and Neurology (Secondary), Yale University	1996-2001
Staff physician, Cross County Neurology,	2001- 2006
Consulting Neurologist, Connecticut Valley Hospital, Middletown, CT	2001- 2006
Staff physician and Co-Director, Headache Center, Associated Neurologists of Southern CT, Fairfield, CT.	2006- 2009
Clinician, Neurology, Yale University School of Medicine	2009-2015

Academic Degrees

MD - Columbia University College of Physicians and Surgeons	1985
Level A, 19 th & 20 th Century Literature + Poetry – Faculté La Sorbonne (Paris)	1990
BS – John Hopkins University	1985
	1984

Residencies and Internships

Neurology – The Neurological Institute of New York (Columbia)	1991- 1994
Internship – St. Vincent's Medical Center, New York	1990- 1991

Fellowships

Clinical Neurology (Substance Abuse) and Neuroscience (Functional Imaging)- Columbia University	1994- 1996
--	------------

Professional Societies

Membership—

American Academy of Neurology	Present
American Headache Society (AHS)	Present

Committee Membership—AHS

a. <u>Education</u>	2011- present
b. <u>Curriculum Development</u> (residency and fellowship programs) -- appointed <u>Committee Chair</u> November, 2013	2011- present
c. <u>Academic Headache Center Directors</u>	2012- present
d. ACHE – <u>Headache Education</u> (Patient Outreach)	2013- present

Editorial Activities

1. **Online Associate Editor, Headache Currents (a journal of the AHS)** Nov 2014-present
2. **(Ad Hoc reviewer)**
 - a. Annals of Neurology (American Neurological Association) 2010-present
 - b. Cephalalgia (International Headache Society) 2012-present
 - c. Headache (Journal of the AHS, American Headache Society) 2012-present

Experience

Private Practice of Neurology:

Associated Neurologists of Southern Connecticut, Fairfield, CT	2006- 2009
Cross County Neurology – Middletown, CT	2001- 2006
Consulting Neurologist – Connecticut Valley Hospital, Middletown, CT	2001- 2006

Attending Neurologist with admission privileges:

Yale-New Haven Medical Center	2009- present
St Vincent's Medical Center, Fairfield, CT	2006- 2009
Milford Hospital, Milford, CT	2006- 2009
Middlesex Hospital, Middletown, CT	2001- 2006
Yale Neurology Clinic (Teaching Attending)	1996- 2001
Attending Physician, Substance Abuse Service – West Haven VA Medical Center	1996- 2001
Clinical Assistant Neurologist - Presbyterian Hospital	1994- 1996
Staff Neurologist –Headache Unit, Montefiore Medical Center	1994- 1996

Publications—

A. Invited Editorial

Telcagepant: almost gone, but not to be forgotten. Cephalalgia 2015. Published Online ahead of print May 5.

B. Peer-reviewed Publications

1. Gottschalk C, Beauvais J, Hart R, Kosten T. Clinical Case Conference: Cognitive Function and Cerebral Perfusion During Cocaine Abstinence. American Journal of Psychiatry 2001; 158 (4): 540-545.
2. Wexler BW, Gottschalk C, Rounsaville BE, Fulbright RK, Prohovnik I, Gore JC. FMR1 of Cocaine Craving. American Journal of Psychiatry 2001; 158: 86-95.
3. Jacobsen LK, Giedd IN, Kreek MJ, Gottschalk C, Kosten TR: Quantitative medial temporal lobe morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report. Drug and Alcohol Dependence 2001; 62(1): 49-56.
4. Jacobsen LK, Geidd IN, Gottschalk C, Kosten TR, and Krystal JH. Quantitative Morphology of the Caudate and Putamen in Cocaine Dependence. American Journal of Psychiatry 2001; 158: 486-489.

5. Gottschalk PC, Kosten TR. Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits. American Journal on Addictions. 2002; 11:200-208
6. Gottschalk PC, Kosten TR. Cerebral perfusion defects in combined cocaine and alcohol dependence. Drug & Alcohol Dependence. 2002; 68:95-104
7. Chang DJ, Zubal IG, Gottschalk C et al. Comparison of statistical parametric mapping and SPECT difference imaging in patients with temporal lobe epilepsy. Epilepsia. 2002; 43:68-74
8. Kosten TR, Gottschalk PC, Tucker K et al. Aspirin or amiloride for cerebral perfusion defects in cocaine dependence. Drug & Alcohol Dependence. 2003; 71:187-194
9. Tucker KA, Browndyke IN, Gottschalk PC et al. Gender-specific vulnerability for rCBF abnormalities among cocaine abusers. Neuroreport. 2004; 15:797-801
10. Kosten TR, Tucker K, Gottschalk PC et al. Platelet abnormalities associated with cerebral perfusion defects in cocaine dependence. Biol Psychiatry. 2004; 55:91-97
11. Browndyke JN, Tucker KA, Woods SP, Beauvais J, Cohen, RA, Gottschalk PCH, Kosten TR. Examining the effect of cerebral perfusion abnormality magnitude on cognitive performance in recently abstinent chronic cocaine abusers. Journal of Neuroimaging. 2004 Apr; 14(2):162-9.
12. Daftary A, Shulman A, Strashun A M, Gottschalk C, Zoghbi SS, Seibyl JP. Benzodiazepine receptor distribution in severe intractable tinnitus. Int Tinnitus J. 2004; 10(1):17-23.
13. Tucker KA, Potenza MN, Beauvais JE, Browndyke IN, Gottschalk PC, Kosten TR. Perfusion abnormalities and decision making in cocaine dependence. Biol Psychiatry. 2004 Oct; 56(7):527-30.
14. Abi-Saab D, Beauvais J, Mehm J, Brody M, Gottschalk C, Kosten TR. The effect of alcohol on the neuropsychological functioning of recently abstinent cocaine-dependent subjects. Am J Addict. 2005 Mar-Apr; 14(2): 166- 78.
15. Staley, JK, Gottschalk, C, Petrakis, IL, Gueorguieva R, O'Malley, S, Baldwin, R, Jatlow, P, Verhoeff, NPLG, Perry, E, Weinzimmer, D, Frohlich, E, Ruff, E, vanDyck, C H, Seibyl, JP, Innis, RB and Krystal, JH. (2005) Cortical GABA_A/benzodiazepine receptors in recovery from alcohol dependence: relationship to feature alcohol dependence and cigarette smoking. Archives of General Psychiatry. 2005 Aug; 62(8):877-88

C. Case Reports, Technical Notes, Letters

- Sewell RA, **Gottschalk CH.** Problem child is no headache. Headache. 2011;51(2):306-7
- Kalp M, **Gottschalk CH.** Mystery case: Heidenhain variant of Creutzfeldt-Jakob disease. Neurology 2014; 83 (22): e187

D. Other Publications-Clinical Reviews

- Gottschalk C, Jacobsen L, Kosten T. Current Concepts in Pharmacotherapy of Substance Abuse-the Dawn of a New Era. 1999 Current Psychiatry Reports 1(2); 172-178.
- Gottschalk C. Stroke; Seizures; Movement Disorders {3 Chapters} In: Brust JC, ed. Neurological Complications of Substance Abuse. Continuum (Continuing Education Monograph Series) Vol. 3 (3). American Academy of Neurology: Williams & Wilkins, 1997:79-87

E. Posters and Presentations

- PCH Gottschalk, Ronald L. Van Heertum, James R. Moeller, and MW Fischman

Cerebral Activation by Cocaine in Humans: Quantitative Studies with Xenon SPECT
Proceedings of the 34th Annual Meeting of the American College of Neuropsychopharmacology;
December 12, 1995, p.185

PCH Gottschalk, PD Esser, TA Pozniakoff, JJ Mann, RS Marshall, RS Tikofsky, and RL Van Heertum
Motor Activation of the Cerebral Cortex: Comparison of O15-H20 PET and Xenon-133-SPECT.
43rd Annual Meeting of the Society of Nuclear Medicine, Denver, Colorado, June 1996. (poster)

PCH Gottschalk, R L Van Heertum, P D Esser, G A Perera, TA Pozniakoff, J R Moeller, WL Young, N D Volkow, RW Foltin and MW Fischman. Cerebral Blood Flow Response to IV Cocaine in Humans: Quantitative Xenon-133-SPECT Studies. 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. San Juan, Puerto Rico; June 26, 1996.

C. Gottschalk, E . Rubin, J. Moeller, R. Van Heertum, and M. Fischman.
Patterns of Cortical Activity Expressed In Quantitative Blood Flow Images During Cocaine Administration: A Placebo-Controlled Time Series Study in Humans With 133-Xenon-SPECT.
Slide Presentation, 27th Annual Meeting of the Society for Neuroscience. New Orleans, L A, November 1 1997.

PCH Gottschalk, H Rinder, J P Seibyl, S Sanabria, and TR Kosten
Anti-Platelet Therapy For Cerebral Blood Flow Deficits In Chronic Cocaine Abusers: Preliminary Results Of Platelet And SPECT Analyses From A Placebo-controlled RCT with Aspirin And Amloride.
Slide presentation, "late-breaking research", 60th Annual Scientific Meeting of the College on Problems of Drug Dependence Scottsdale, AZ; June 1998.

Gottschalk C , Rinder H , Sanabria S , Seibyl J , Dey H , and Kosten T
Antiplatelet Therapy for Regional Cerebral Perfusion Deficits in Chronic Cocaine Abusers.
Slide Presentation, 28th Annual Meeting of the Society for Neuroscience. Los Angeles, CA, November 1998.

P. C. H. Gottschalk, J., Seibyl, H., Rinder, and T. R. Kosten
Treatment of cocaine-related cerebral perfusion deficits with anti-platelet agents: SPM analyses of early abstinence. Poster, 6¹st Annual Scientific Meeting of the College on Problems of Drug Dependence. Acapulco, Mexico; June 1999.

C. Gottschalk, J. Seibyl, H. Dey, and T. Kosten.
Isradipine Treatment for Chronic Cerebral Perfusion Deficits in Cocaine Dependence.
Poster presentation, 29th Annual Meeting of the Society for Neuroscience. Miami, FL, October 1999

Gottschalk C, Nichols T, Feingold A, Kosten T.
Assessment of Medication Effects in Neuroimaging Using Quadratic Models
Poster, sixth annual meeting of the Organization for Human Brain Mapping, San Antonio, Texas, June 12-16, 2000

P.C. Gottschalk, H., Rinder, J. Seibyl T, R. Kosten
Cerebral Perfusion Deficits in Chronic Cocaine Abusers: Short-term Antiplatelet Therapy in 73 patients
Poster presentation, 30th Annual Meeting of the Society for Neuroscience. New Orleans, L A October 2 000

PC Gottschalk, TR Kosten
Gender differences in cocaine-associated cerebral blood flow abnormalities
Slide Presentation, 63rd Annual Scientific Meeting of the College on Problems of Drug Dependence. Scottsdale, AZ June 2001

GRANTS

NIDA P50 DA09236 Medication Development Center Grant

Principal Investigator, Project 3: Physiological effects of acute cocaine. 1994-96.

Recent Pharmaceutical Research Activities

As interim director of the Yale MS Center from June, 2009 to October, 2011, I assumed the role of PI on several multi-center clinical trials:

A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Nerispiridine 50 mg, 100 mg and 200 mg in Patients with Multiple Sclerosis”

A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Patients with Relapsing Remitting Multiple Sclerosis Who Have Relapsed on Therapy”

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects with Relapsing Remitting Multiple Sclerosis”

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing Remitting Multiple Sclerosis”

A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing Remitting Multiple Sclerosis”

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients with Multiple Sclerosis Who Participated in the MS-F204 Trial”

A Multi-Center, Dose-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis”

A 24-Month, Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients with Relapsing Remitting Multiple Sclerosis with Optional Extension Study”

Open-Label Study to Evaluate the Safety of Copaxone and to Monitor the Neurological Course of Disease in Multiple Sclerosis Patients Treated with Copaxone”

JCV Antibody Program in Patients with Relapsing Remitting Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2”

While at Associated Neurologists of Southern Connecticut I was sub-Investigator on several pharmaceutical trials:

A Multi-Center, Multinational, Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial of the Efficacy and Safety of Compound (z target doses) in Subjects with Advanced Stage, Idiopathic Parkinson’s Disease who are not well controlled on Levodopa (Part I) and Open-Label Extension to Assess the Safety of Long-Term Treatment of Compound (Part II). 2007-2009

Prevention Regimen for Effectively avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled study of a compound versus another compound + aspirin, with and without a third compound.” PRoFESS Trial. 2006-7

“A Multi-center, Double-Blind, Placebo controlled, Parallel Group Safety Study of Pulmonary function in Patients with Reduced Lung Function treated with BOTOX® Purified Neurotoxin Complex for Focal Upper Arm Limb Spasticity Due to Upper Motor Neuron Syndrome.” 2007-2009

“PREEMPT Trial: Botox vs. placebo in chronic daily headache.” 2006-2009

“A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in *APOE* ϵ 4-stratified subjects with mild to moderate Alzheimer’s disease.”
(REFLECT-1) 2007- 2009